We are live on
!
Find out more
FCM
Farallon Capital Management Portfolio holdings
AUM
$17.5B
1-Year Est. Return
50.95%
This Fund
S&P 500
This Quarter
Est. Return
+25.17%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$14.8B
AUM Growth
+$1.58B
(+12%)
Cap. Flow
-$1.22B
Cap. Flow
% of AUM
-8.22%
Top 10 Holdings %
Top 10 Hldgs %
44.34%
Holding
132
New
32
Increased
38
Reduced
29
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$317M |
| 2 |
Salesforce
CRM
|
+$270M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$259M |
| 4 |
MDCO
Medicines Co
MDCO
|
+$221M |
| 5 |
PPLI
People Inc
PPLI
|
+$137M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.55B |
| 2 |
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
|
+$754M |
| 3 |
AABA
Altaba Inc
AABA
|
+$666M |
| 4 |
Alibaba
BABA
|
+$196M |
| 5 |
CTXS
Citrix Systems Inc
CTXS
|
+$183M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.48% |
| 2 | Communication Services | 11.12% |
| 3 | Technology | 9.77% |
| 4 | Industrials | 5.05% |
| 5 | Financials | 3.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
76
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $22.6M | 0.15% |
175,000
-125,000
| -42% | -$12.1M |
|
|
PRNB
77
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $21.9M | 0.15% |
+400,000
| New | +$14.9M |
|
78
Savara
SVRA
$1.19B
| $21.6M | 0.15% |
4,825,086
+1,314,299
| +37% | +$1.58M |
|
|
AMRN
79
CALL
Amarin Corp
AMRN
$301M
| $21.4M | 0.14% |
+50,000
| New | +$19M |
|
80
CRISPR Therapeutics
CRSP
$4.99B
| $21.3M | 0.14% |
350,000
-210,367
| -38% | -$11.5M |
|
|
WMGI
81
DELISTED
Wright Medical Group Inc
WMGI
| $21M | 0.14% |
+690,000
| New | +$18.1M |
|
82
Heron Therapeutics
HRTX
$94.5M
| $20.6M | 0.14% |
+875,000
| New | +$19.4M |
|
|
CY
83
DELISTED
Cypress Semiconductor
CY
| $19.6M | 0.13% |
840,000
-1,624,966
| -66% | -$38M |
|
84
Gen Digital
GEN
$16.8B
| $18.4M | 0.12% |
720,000
-310,000
| -30% | -$7.57M |
|
|
S
85
DELISTED
Sprint Corporation
S
| $16.7M | 0.11% |
3,200,000
-3,034,186
| -49% | -$17.8M |
|
|
EIGR
86
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $16.3M | 0.11% |
36,485
-1,015
| -3% | -$360K |
|
87
Pacific Biosciences
PACB
$363M
| $15.4M | 0.1% |
+3,000,000
| New | +$15.2M |
|
|
RETA
88
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $15.3M | 0.1% |
75,000
-107,060
| -59% | -$19.5M |
|
|
APLS
89
DELISTED
Apellis Pharmaceuticals
APLS
| $15.3M | 0.1% |
+500,000
| New | +$13.8M |
|
|
LVGO
90
DELISTED
Livongo Health, Inc. Common Stock
LVGO
| $15M | 0.1% |
+600,000
| New | +$14.3M |
|
91
Exagen
XGN
$160M
| $14.7M | 0.1% |
577,699
+214,363
| +59% | +$3.81M |
|
92
uniQure
QURE
$3.15B
| $14.3M | 0.1% |
200,000
+99,078
| +98% | +$5.44M |
|
|
LOGM
93
DELISTED
LogMein, Inc.
LOGM
| $11.2M | 0.08% |
+130,241
| New | +$9.66M |
|
94
Protagonist Therapeutics
PTGX
$9.4B
| $10.6M | 0.07% |
1,500,000
| – | – |
|
|
OPTN
95
DELISTED
OptiNose
OPTN
| $8.3M | 0.06% |
+60,000
| New | +$7.78M |
|
96
Rocket Pharmaceuticals
RCKT
$387M
| $8.06M | 0.05% |
+354,082
| New | +$5.91M |
|
|
GCVRZ
97
DELISTED
Sanofi Contingent Value Rights
GCVRZ
| $7.91M | 0.05% |
9,195,584
+2,367,779
| +35% | +$1.82M |
|
98
Gossamer Bio
GOSS
$87.2M
| $7.82M | 0.05% |
500,000
+399,288
| +396% | +$8.04M |
|
|
DMTK
99
DELISTED
DermTech, Inc. Common Stock
DMTK
| $7.63M | 0.05% |
615,385
| – | – |
|
100
Abeona Therapeutics
ABEO
$393M
| $6.54M | 0.04% |
+80,000
| New | +$5.64M |
|
Similar funds
BBA
MCM
LA
CM
ASRS
PP
VMPIC
HNB
Farallon Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Farallon Capital Management held 132 positions worth $14.8B, up 12% from $13.2B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Farallon Capital Management withdrew a net $1.22B in Q4 2019, closing 16 positions and reducing 29 holdings. Its most notable exit was Celgene Corp, an estimated $1.55B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 40% a quarter earlier, followed by Communication Services and Technology.
Against the trend, Farallon Capital Management opened a new position in Salesforce worth $281M.
- Farallon Capital Management's largest Q4 2019 buy was Salesforce: 1,724,880 shares worth $281M.
- Farallon Capital Management added most to Allergan plc in Q4 2019, an estimated $317M increase.
- Farallon Capital Management's biggest Q4 2019 reduction was Broadmark Realty Capital Inc. Common Stock, cutting an estimated $754M.
- Farallon Capital Management fully exited Celgene Corp in Q4 2019, selling an estimated $1.55B.
- Farallon Capital Management's ten largest holdings make up 44% of its $14.8B portfolio in Q4 2019.
- Farallon Capital Management opened 32 new positions and closed 16 in Q4 2019.
- Farallon Capital Management's portfolio value rose 12% quarter-over-quarter to $14.8B.
Based on Farallon Capital Management's 13F filing for Q4 2019, filed 13 Feb 2020.